National and Kapodistrian University of Athens
Δίαιτα χαμηλή σε ζυμώσιμους ολιγοσακχαρίτες, δισακχαρίτες, μονοσακχαρίτες και πολυόλες, προσαρμοσμένη στη μεσογειακή διατροφή και εφαρμογή σε ασθενείς με ευερέθιστο έντερο: εκτίμηση συμμόρφωσης και ανακούφισης των συμπτωμάτων
Abstract
dc:descriptionIrritable bowel syndrome (IBS) affects approximately 20% of the population, and it is often associated with food intake. The low FODMAP diet (LFD) is effective for managing IBS symptoms, but its anti-inflammatory potential remains unclear. The Mediterranean diet (MedDiet) is known for its significant anti-inflammatory properties. This thesis protocol introduces the MED-LFD, which combines the symptom relief of LFD with the anti-inflammatory benefits of the MedDiet. To evaluate the effectiveness of the Mediterranean version of the low FODMAPs Diet (MED-LFD) compared to NICE guidelines for IBS symptoms' management and to assess changes in stool short and branched-chain fatty acid levels (SCFAs and BCFAs). 108 patients with Rome IV IBS without constipation were randomized into the MED-LFD or NICE group. Primary endpoints included changes in symptom severity and responder rate (reduction of more than 50 IBS-SSS points) after intervention and at six months of follow-up. Secondary endpoints assessed quality of life, symptom burden, adequate relief, anxiety/depression levels, adherence, and safety. Stool SCFA and BCFA levels were measured using Gas Chromatography/Mass Spectrometry. We registered this Thesis Protocol under ClinicalTrials.gov ID: NCT03997708. At both time points, the MED-LFD group showed a significantly greater improvement in symptom severity (159±80 vs. 253±94 and 168±117 vs. 245±98), responder rates (84.6% vs. 60.8% and 79.1% vs. 52.3%), and adherence (75% vs. 41% and 45% vs. 7%). Similar results were observed for all secondary endpoints, with no serious adverse events reported. The MED- LFD intervention was the strongest independent predictor of being a responder at the 1st (OR=6.66; 95%CI=1.46, 30.4) and 2nd follow-up (OR=4.85; 95%CI=1.31, 17.96). Stool SCFAs and BCFAs were significantly reduced at both follow-ups. The MED-LFD is superior to NICE recommendations in managing non- constipated IBS symptoms and quality of life. It remains to be proved that reduced stool SCFA and BCFA levels might be an objective marker of response to dietary interventions.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kasti, Arezina
- Καστή, Αρεζίνα
Subjects
dc:subject × 16- Σύνδρομο Eυερέθιστου Eντέρου
- Ανακούφιση συμπτωμάτων
- Δίαιτα χαμηλή σε FODMAP
- Μεσογειακή διατροφή
- Λιπαρά οξέα βραχείας και διακλαδισμένης αλύσου
- Irritable bowel syndrome
- Low FODMAP Diet
- Mediterranean diet
- SCFAs/BCFAs
- Symptom relief
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Διατροφή και Διαιτολογία
- Health Sciences
- Medical and Health Sciences
- Nutrition and Dietetics
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59512